Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 5/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2959851 | 0.78 | CYSLTR2 (0.34) | — | |
| SCHEMBL2970949 | 0.76 | SKP2 (0.40) | CA2SMN1; SMN2SKP2SPHK1HTR2A | |
| SCHEMBL2962627 | 0.74 | HSD11B1 (0.36) | CA2SMN1; SMN2HSD11B1CA1ALDH1A1 | |
| SCHEMBL2961226 | 0.74 | SKP2 (0.40) | CA2SMN1; SMN2SKP2SPHK1HTR2A | |
| SCHEMBL2969034 | 0.66 | CA2 (0.34) | CA2SMN1; SMN2SKP2SPHK1HSD11B1 | |
| SCHEMBL2972370 | 0.64 | HSD11B1 (0.37) | CA2SMN1; SMN2HSD11B1CA1ALDH1A1 | |
| SCHEMBL168272 | 0.63 | CA2 (0.56) | CA2SMN1; SMN2SKP2HSD11B1HTR2A | |
| P-Xylene SCHEMBL9064447 | 0.63 | CA2 (0.56) | CA2SMN1; SMN2SKP2HSD11B1HTR2A | |
| SCHEMBL18462106 | 0.63 | HSD11B1 (0.41) | CA2SMN1; SMN2SKP2HSD11B1CNR2 | |
| SCHEMBL83869 | 0.63 | CA2 (0.65) | CA2SMN1; SMN2SKP2HTR2ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763562-B2 | Heteroatom bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070135597-A1 | Heteroatom bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135597-A1 | Heteroatom bridged metallocene compounds for olefin polymerization | AP2M1, AP1M1, PYM1 | CA2 3440/4885SMN1; SMN2 4156/4885SKP2 2873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.